Head-to-head · WeighScore
Invigor Medical vs KERNX Health
By GLP-1 ScorecardUpdated
Score comparison
Invigor Medical has the higher recorded score — 86.1/100 to 71.8/100.
Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Now Try Invigor, this platform advertises class-based GLP-1 plans; confirm your medicine and supply before accepting its starting price.
Before you choose
Before comparing the headline prices, the Invigor Medical review and the KERNX Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Invigor Medical vs Kina and KERNX Health vs MadeMed compare each of them with another graded program, and the list of alternatives to Invigor Medical ranks the programs closest to Invigor Medical on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Bodybuilding Health+ review covers one graded close to these two, at 78.1/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Invigor Medical | KERNX Health |
|---|---|---|
| WeighScore | 86.1/100 | 71.8/100 |
| Grade | B | C |
| Site position | #9 | #97 |
| Semaglutide | Medication-specific quote unconfirmed; public GLP-1 treatment starts at $225. | Advertised $209 per four-week supply (compounded injection); oral $279 |
| Tirzepatide | Medication-specific quote unconfirmed; public GLP-1 + GIP treatment starts at $350/month. | Advertised $299 per four-week supply (compounded injection) |
| Coverage | U.S. only; confirm medication-specific state availability | Provider network advertises all 50 states; confirm treatment availability |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Yes |
Strengths
- Consultation, medication and supplies advertised together
- Ordinary and microdose treatment listings are separately presented
- Clinical policy describes virtual consultation and relevant testing when needed
What to consider
- Current medication-specific dose and supply quote is unconfirmed
- Cancel new orders before the prescription enters the practitioner's queue
- Subscriptions need seven days’ notice before renewal processing; charges may occur early
- No universal GLP-1 lab panel, frequency or separate testing price published
Strengths
- Advertised pricing separates single-supply rates from prepaid totals
- Published terms include coaching, shipping and provider-ordered testing in month two
What to consider
- Prepaid terms can renew automatically for the selected period
- Later testing costs and the assigned pharmacy need confirmation
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.